| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Monday, August 03, 2026 01:40 PM
Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies ...
|
|
Monday, August 03, 2026 09:35 AM
The gross proceeds to Apnimed from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/08/26 | 24.29 | 27.91 | 22.35 | 25.00 | 700,231 |
|
|
||||
|
|
||||
|
|